MEDraysintell publishes the 8th. Edition of its Nuclear Medicine Report & Directory
MEDraysintell comes out on the 8th Edition of the Nuclear Medicine Report and Yearbook-2021, a set of three volumes aimed at providing a complete and exhaustive review of the global nuclear medicine landscape, through a detailed analysis of existing marketed products and through the description and evaluation of the potential of radiopharmaceuticals in clinical development or at an early stage and associated companies active in this field.
This new Edition-2021 provides in 3,100 pages a description of 870 products, as well as a complete profile of 340 companies active worldwide in the radiopharmaceutical industry.
The number of direct Internet links to bibliographic references has been increased to 2,700.
◼ MEDraysintell Nuclear Medicine (Part 1) – Marketed radiopharmaceuticals
◼ MEDraysintell Nuclear Medicine (Part 2) – Clinical Radiopharmaceuticals
◼ MEDraysintell Nuclear Medicine (Part 3) – Early stage radiopharmaceuticals
In addition, a database containing all clinical and early stage radiopharmaceuticals described in the reports can also be provided to assist users in their searches.
MEDraysintell estimates that the global nuclear medicine market reached just over US $ 5.6 billion in 2020, down almost 5% from 2019. This drop is a direct consequence of the COVID-pandemic. 19, mainly observed in the first half of 2020. With the lockdown of most countries and the major restriction of air travel, the transport of radionuclides and radiopharmaceuticals has become the main bottleneck for distributing these products to hospitals. However, the situation returned to near normal at the end of 2020.
In recent years, a growing interest of private investors and conventional pharmaceutical industries in the nuclear medicine market has continued to be observed, despite the pandemic, of course mainly in the therapeutic area. It has also led to significant M&A activity. Over US $ 17 billion was invested in M&A transactions between 2014 and June 2021. In addition to M&A activity, nearly 50 radiopharmaceutical companies were able to raise a total of nearly US $ 4 billion as of January 2019 to June 2021, to finance their development. New opportunities for development, investments, mergers and acquisitions are emerging.
Despite the fact that most nuclear medicine-related congresses have gone virtual in the past year due to the COVID-19 pandemic and difficulties in making in-person contact, MEDraysintell has been able to refine its data collection with more precise information as new information became available. . These three documents are intended to assist the reader in developing their strategies in this industry.